ArticleTranslational cancer research2025

The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.

Tasuku Matsuoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.